LifeMD, Inc. financial statements

Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data LifeMD, Inc. files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	5.24	5	8.32	12.5	37.3	92.9	119	153	155	194
Cost of revenue	1.95	1.02	2	2.53	8.86	18	18.7	18.9	21.4	27.7
Gross profit	3.29	2.66	6.33	9.94	28.4	74.9	100	134	133	166
Selling and marketing			5.08	8.92	39.1	82.5	78.4	76.5	70.1	86.1
General and administrative	1.03	0.74	2.29	2.4	45	39.5	47	51.7	57.9	57.9
Operating expenses	4.47	3.89	8.38	12.8	86.3	129	144	148	154	174
Operating income	-1.17	-1.23	-2.06	-2.89	-57.8	-54.3	-43.4	-14.5	-20.4	-7.67
Interest expense	0.05	0.1	0.35	0.76	1.67	3.02	1.28	2.6	2.18	1.36
Other non-operating income	-1.22	-1.22		-0.76	-2.58
Pre-tax income	-1.22	-1.38	-2.41	-3.65	-60.4	-61.3	-44.7	-17.4	-22.6	-10.2
Income tax			-0.12	-0.12	0.12	0.01	0.36	0.43	0.6	0.05
Income from continuing operations									-23.2	-10.2
Net income to minority interests	-0.12	-0.01	-0.12	-0.39	-1.88	-0.43	0.51	2.76	0.55	1.27
Net income	-1.11	-1.21	-1.24	-3.14	-58.6	-60.9	-45.5	-20.6	-21.4	14.4
EBITDA						-54.3	-43.3	-14.3	-19.9	-6.8
EPS, basic	-0.03	-0.03							-0.60	0.25
EPS, diluted	-0.03	-0.03							-0.60	0.25
Shares, basic (weighted)	33.5	41.7	44.2	9.9	14.3	27	31	33.9	41.2	45.1
Shares, diluted (weighted)	33.5	41.7	44.2	9.9	14.3	27	31	33.9	41.2	45.1

Balance sheet

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Cash and equivalents	0.18	0.14	0.18	1.11	9.18	41.3	3.96	33.1	35	36.8
Receivables	0.44	0.13	0.1	0.1	1	0.98	2.83	6.27	10.5	9.31
Inventory	0.16	0.68	1.02	0.95	1.26	1.62	3.7	2.76	2.8	2.77
Other current assets			0.27	0.44	0.15	0.79	0.69	0.93	3	2.65
Total current assets	0.79	1.26	1.61	2.75	12.4	44.9	11.3	42.6	52.4	51.8
Property, plant and equipment						0.23	0.48	0.48	1.44	2.44
Lease right-of-use assets				0.02	0.27	1.75	1.21	0.59	6.23	5.27
Goodwill						0	8
Intangible assets			1.01	0.68	0.34	0.02	3.83	3.01	0.05	0.26
Total assets	0.79	1.26	2.62	3.45	13.4	49.9	25.7	58.5	76.1	70.4
Accounts payable	0.75	0.42	0.87	3.05	10.4	9.06	10.1	11.1	10.9	14.1
Accrued liabilities						11.6	12.2	13.9	21.8	16
Deferred revenue			0.08	0.11	0.92	1.5	5.5	7.27	17.1	10.8
Total current liabilities	1.15	0.64	1.19	3.98	13.9	22.8	31.4	34.8	67.4	41.6
Long-term debt		0.17	0.25
Lease liabilities					0.19	1.18	0.57	0.07	6.28	5.68
Total liabilities	1.15	0.64	1.8	4.58	14.2	24.1	33	52.9	83.7	47.3
Paid-in capital	9.07	11.5	12.7	15.7	77.8	165	179	218	231	251
Retained earnings	-9.69	-10.9	-12.1	-16.6	-80.2	-142	-191	-214	-240	-229
Treasury stock	-0.09	-0.16	-0.16	-0.16	-0.16	-0.16	-0.16	-0.16	-0.16	-0.16
Shareholders' equity	-0.36	0.88	0.9	-0.99	-2.3	22.7	-11.4	3.51	-9.08	23.2
Minority interests	-0.01	-0.26	-0.08	-0.14	-2.18	-1.03	-0.48	2.06	1.53
Total equity	-0.36	0.62	0.82	-1.13	-4.48	21.7	-11.9	4.19	-7.55	23.2
Total liabilities and equity	0.79	1.26	2.62	3.45	13.4	49.9	25.7	58.5	76.1	70.4
Shares outstanding	35.2	44	45.3	10.6	23.3	30.6	31.4	38.3	42.2	46.7

Cash flow statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Net income	-1.22	-1.22	-1.36	-3.53	-60.5	-61.3	-45	-17.8	-20.9	15.6
Depreciation and amortization						0.01	0.16	0.2	0.47	0.87
Stock-based compensation	0.59	0.16	0.27	0.73	18.7	12.1	13.7	12.5	12.2	10.5
Deferred income tax				0.07	-0.07		0.35
Change in receivables	-0.36	0.1	0.03	0	-0.82	0.02	-2.19	-2.44	-4.49	1.15
Change in inventory	-0.1	-0.55	-0.34	0.07	-0.31	-0.41	-2.18	0.41	-0.71	0.02
Change in payables						-0.89	1.25	0.98	4.18	3.24
Cash from operations	-0.41	-0.82	-0.91	0.25	-12.1	-33.1	-22.9	8.82	17.5	8.28
Capital expenditures						-0.25	-0.37	-0.2	-1.46	-1.87
Acquisitions			-0.15				-1.01
Cash from investing			0.14	-0.1	-0.8	-3.4	-13.9	-8.73	-11.5	6.91
Debt issued						15
Debt repaid				-0.28		-15				-18.7
Stock issued	-0.09	0.67	0	0.35	2.34	0.49	0.09	10	0.12	8.72
Share buybacks		-0.08		-0.35						-0.27
Dividends paid						-0.87	-3.11	-3.11	-3.11	-3.11
Cash from financing	0.36	0.78	0.8	0.78	21	68.6	-0.53	29.1	-4.12	-13.4
Net change in cash	-0.05	-0.04	0.04	0.93	8.07	32.1	-37.4	29.2	1.86	1.78
Free cash flow						-33.3	-23.3	8.62	16	6.41
Interest paid	0.01	0	0	0.08	1.67	0.44	0.19	2.15	2.53	1.46
Income taxes paid									0.21	0.59

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $23.15 on September 25, 2026.

Profitability

Metric	Value	How it is calculated
Gross margin	87.5%	Gross profit / revenue.
Operating margin	-10.5%	Operating income / revenue.
EBITDA margin	-10.0%	EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin	-13.2%	Pre-tax income / revenue.
Net margin	0.1%	Net income / revenue.
FCF margin	-5.8%	Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin	-5.2%	Cash from operations / revenue.
Return on equity (ROE)	2.5%	Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)	0.3%	Net income / average total assets.
Stock-based pay / revenue	4.2%	Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue	0.6%	Capital expenditures / revenue.
D&A / revenue	0.6%	Depreciation and amortization / revenue.

Growth

Metric	Value	How it is calculated
Revenue growth, 1y	25.3%	Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y	17.7%	Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y	39.1%	Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y	24.7%	Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y	18.3%	Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y	42.4%	Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating cash flow growth, 1y	-52.7%	Operating cash flow vs the same period a year earlier. Only from a positive base.
Free cash flow growth, 1y	-60.1%	Free cash flow vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y	-7.5%	Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y	40.0%	Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y	39.3%	Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y	9.5%	Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y	13.4%	Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y	25.9%	Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

Metric	Value	How it is calculated
Current ratio	0.90x	Current assets / current liabilities.
Quick ratio	0.78x	(Cash + short-term investments + receivables) / current liabilities.
Cash ratio	0.54x	(Cash + short-term investments) / current liabilities.
Liabilities / assets	86.7%	Total liabilities / total assets.
Working capital	-$4.5M	Current assets - current liabilities.
Goodwill and intangibles / assets	0.3%	(Goodwill + intangible assets) / total assets.
Tangible book value	$7.8M	Shareholders' equity - goodwill - intangible assets.

Efficiency

Metric	Value	How it is calculated
Asset turnover	3.20x	Revenue / average total assets.
Fixed asset turnover	94.1x	Revenue / average property, plant and equipment.
Inventory turnover	7.73x	Cost of revenue / average inventory.
Days inventory	47 days	365 x average inventory / cost of revenue.
Receivables turnover	17.0x	Revenue / average receivables.
Days sales outstanding	21 days	365 x average receivables / revenue.
Days payables	290 days	365 x average accounts payable / cost of revenue.
Cash conversion cycle	-221 days	Days inventory + days sales outstanding - days payables.
FCF conversion	-5,501.0%	Free cash flow / net income, when net income is positive.

Per share

Metric	Value	How it is calculated
EPS, diluted	$0.00	Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share	$4.01	Revenue / diluted weighted shares.
FCF per share	-$0.23	Free cash flow / diluted weighted shares.
Operating cash flow per share	-$0.21	Cash from operations / diluted weighted shares.
Book value per share	$0.17	Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share	$0.16	Tangible book value / shares outstanding.
Cash per share	$0.53	(Cash + short-term investments) / shares outstanding.
Payout ratio	1,545.0%	Dividends paid / net income, when net income is positive.

Valuation

Metric	Value	How it is calculated
Market cap	$1.12B	Share price x shares outstanding.
Enterprise value	$1.09B	Market cap + total debt - cash - short-term investments.
P/E	5,551x	Market cap / net income. Only when net income is positive.
P/S	5.82x	Market cap / revenue.
P/B	140x	Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book	144x	Market cap / tangible book value, when positive.
EV/Sales	5.69x	Enterprise value / revenue.
FCF yield	-1.0%	Free cash flow / market cap.
Earnings yield	0.0%	Net income / market cap (the inverse of P/E).
Dividend yield	0.3%	Dividends paid over the period / market cap.
Shareholder yield	0.3%	(Dividends paid + share buybacks) / market cap.

What was LifeMD, Inc.'s revenue in fiscal 2025?

LifeMD, Inc. reported revenue of $194.1M for fiscal 2025, 25.3% higher than the year before.

Was LifeMD, Inc. profitable in fiscal 2025?

Yes. Net income was $14.4M, a net margin of 7.4%.

How much free cash flow did LifeMD, Inc. generate in fiscal 2025?

Cash from operations of $8.3M minus capital expenditures of $1.9M left free cash flow of $6.4M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to LifeMD, Inc.